Novartis’ Biogeneric Pipeline Has Six Projects; Pricing Issues Are A Focus

Novartis expects to file its second biosimilar application in the coming year, Sandoz CEO Andreas Rummelt stated during the Swiss drug maker's first quarter sales and earnings call April 24